Merck moving to Phase 2 study of drug-eluting implant to prevent HIV infection

By Sean Whooley | March 8, 2021

Merck (NYSE:MRK) today announced positive results from a Phase 1 study of its subdermal drug-eluting implant for preventing HIV-1 infection.

The investigational implant has the potential for extended administration of islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Filed Under: clinical trials, Drug Delivery, Drug Discovery, Drug Discovery and Development
Tagged With: HIV, Merck

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.